Loading
institutionsInstitution
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
NYU's cancer centre, comprehensive since 2019, known for melanoma immunotherapy, RAS and SHP2 biology, and early deep-learning pathology.
Also called: Perlmutter Cancer CenterNYU Cancer Institute
Overview
NCI-designated since the 1970s and comprehensive since 2019, Perlmutter Cancer Center spans NYU Langone's Manhattan, Brooklyn and Long Island hospitals. Its melanoma programme (Jeffrey Weber, Iman Osman, Anna Pavlick) led adjuvant nivolumab trials; Benjamin Neel, the director, discovered the phosphatase SHP2 (PTPN11), now a drug target in RAS-driven cancers; Dafna Bar-Sagi's laboratory defined how KRAS-mutant pancreatic cancers scavenge nutrients. Aristotelis Tsirigos's 2018 study of deep learning on lung cancer histology slides was an early landmark in computational pathology. Michele Pagano's work on ubiquitin ligases underpins targeted protein degradation.
Location
New York, NY, US
Type
cancer center · New York University
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#60 · 47 points (0 Newsweek + 15 NCI + 32 from 16 linked objects) · ranking
- Melanoma immunotherapy
- RAS and SHP2 biology
- Computational pathology
Arjun V. Balar
Professor of Medicine and Director, Genitourinary Medical Oncology Program, NYU Langone Perlmutter Cancer Center
Urothelial cancerFirst-line immunotherapyNon-muscle-invasive bladder cancer
Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer.
Douglas A. Levine
Director of Gynecologic Oncology, NYU Langone Perlmutter Cancer Center
Gynaecologic oncology surgeryEndometrial cancer genomicsOvarian cancer genomics
Surgeon-scientist who led the TCGA endometrial cancer study that created today's four molecular subtypes.
Jeffrey S. Weber
Deputy Director, NYU Langone Perlmutter Cancer Center; Professor of Medicine
MelanomaAdjuvant immunotherapyCancer vaccines
Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942.
reviewInternational Journal of Cancer 20261 citation
Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium
The current honest statement of where early detection stands: no blood test is ready, and the research is about finding the threshold at which to operate.
guidelineGastroenterology 202137 citations
Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium
PRECEDE is the infrastructure answer to CAPS's problem: no single centre can enrol enough high-risk people to validate an early detection test.
Similar pages
- PersonDiane M. Simeone
Shares Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium, Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium, Pancreatic ductal adenocarcinoma.
- TrialPRECEDE
Shares Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium, Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium, Pancreatic ductal adenocarcinoma.
- InstitutionCentro Nacional de Investigaciones Oncológicas (CNIO)
Shares The undruggable drivers, KRAS, Melanoma, Pancreatic ductal adenocarcinoma.
- TrialCheckMate 238
Shares Jeffrey S. Weber, Nivolumab, PD-1, Melanoma.
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares The undruggable drivers, KRAS, Pancreatic ductal adenocarcinoma.
- TrialCheckMate 204
Shares Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Nivolumab, PD-1, Melanoma.
- InstitutionUPMC Hillman Cancer Center
Shares Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), National Cancer Institute (NIH), Melanoma.
- CompanyFrontier Medicines
Shares The undruggable drivers, KRAS, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
cancers
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
institutions
people
bottlenecks
key papers
Open-source projects
All open source in oncology →Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
NYU's deep neural network for screening mammography interpretation, with weights and code released.
890 starslast push 2023-12-14Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthRepositoryNYU's globally-aware multiple instance classifier for high-resolution mammograms.
189 starslast push 2024-07-25Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthRepositoryContainers and scripts to run and compare published mammography AI models on new datasets.
72 starslast push 2022-08-15Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthRepository